Literature DB >> 2784203

Cell type-specific transcriptional regulation of the human adenosine deaminase gene.

D L Lattier1, J C States, J J Hutton, D A Wiginton.   

Abstract

The relative rates of transcription of the human adenosine deaminase (ADA) gene were determined in isolated nuclei from T and B lymphoblasts and skin fibroblasts. ADA gene transcription occurs at higher rates in T cells than in B cells and fibroblasts. Relative steady state ADA mRNA levels were also determined for each cell line, and these values were found to correlate with relative rates of transcription of the gene. Therefore, the primary mechanism for control of expression of this ubiquitous enzyme is at the level of transcription. The ratios of ADA enzymatic activity to specific mRNA content were also compared between cell lines. The B lymphoblasts exhibited lower ratios than did the T lymphoblasts, suggesting that rates of protein degradation were several fold greater in B than in T lymphoblast cell lines. This finding is consistent with previous direct measurements of ADA protein turnover. Differential rates of protein turnover in B as compared to T cells provide a secondary mechanism for the regulation of ADA expression. In addition to transcription initiation being the major control mechanism of steady state ADA mRNA in all cell lines, first intron elongation pausing occurs in fibroblasts, and discrete regions of RNA polymerase II and RNA polymerase III antisense transcripts are observed in all cell lines studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784203      PMCID: PMC331722          DOI: 10.1093/nar/17.3.1061

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  24 in total

1.  Micromethod for quantitation of adenosine deaminase activity in cells from human peripheral blood.

Authors:  M S Coleman; J J Hutton
Journal:  Biochem Med       Date:  1975-05

2.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

3.  Synthesis of messenger RNA-like molecules in isolated myeloma nuclei.

Authors:  Y Y Mory; M L Gefter
Journal:  Nucleic Acids Res       Date:  1977-06       Impact factor: 16.971

Review 4.  Biochemistry of diseases of immunodevelopment.

Authors:  D W Martin; E W Gelfand
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

5.  Human adenosine deaminase. Properties and turnover in cultured T and B lymphoblasts.

Authors:  P E Daddona
Journal:  J Biol Chem       Date:  1981-12-10       Impact factor: 5.157

6.  Cloning and characterization of nine heat-shock-induced mRNAs of Drosophila melanogaster.

Authors:  J T Lis; W Neckameyer; R Dubensky; N Costlow
Journal:  Gene       Date:  1981-10       Impact factor: 3.688

7.  Transcriptional regulation of the ovalbumin and conalbumin genes by steroid hormones in chick oviduct.

Authors:  G S McKnight; R D Palmiter
Journal:  J Biol Chem       Date:  1979-09-25       Impact factor: 5.157

8.  X-ray intensifying screens greatly enhance the detection by autoradiography of the radioactive isotopes 32P and 125I.

Authors:  R Swanstrom; P R Shank
Journal:  Anal Biochem       Date:  1978-05       Impact factor: 3.365

9.  An immunomorphologic study of adenosine deaminase distribution in human thymus tissue, normal lymphocytes, and hematopoietic cell lines.

Authors:  B E Chechik; W P Schrader; J Minowada
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

10.  Antisense RNA inhibits splicing of pre-mRNA in vitro.

Authors:  S H Munroe
Journal:  EMBO J       Date:  1988-08       Impact factor: 11.598

View more
  24 in total

1.  In vitro analysis of a transcription termination site for RNA polymerase II.

Authors:  D K Wiest; D K Hawley
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Control of formation of two distinct classes of RNA polymerase II elongation complexes.

Authors:  N F Marshall; D H Price
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

3.  Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes.

Authors:  J Venema; A van Hoffen; V Karcagi; A T Natarajan; A A van Zeeland; L H Mullenders
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

4.  Sequence requirements for premature transcription arrest within the first intron of the mouse c-fos gene.

Authors:  N Mechti; M Piechaczyk; J M Blanchard; P Jeanteur; B Lebleu
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

Review 5.  Regulation of eukaryotic gene expression by transcriptional attenuation.

Authors:  S Wright
Journal:  Mol Biol Cell       Date:  1993-07       Impact factor: 4.138

6.  Deficient repair of the transcribed strand of active genes in Cockayne's syndrome cells.

Authors:  A van Hoffen; A T Natarajan; L V Mayne; A A van Zeeland; L H Mullenders; J Venema
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

7.  In vivo transcriptional pausing and cap formation on three Drosophila heat shock genes.

Authors:  E B Rasmussen; J T Lis
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

8.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

Authors:  E H Chen; E E Johnson; S M Vetter; B S Mitchell
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  The genetic defect in Cockayne syndrome is associated with a defect in repair of UV-induced DNA damage in transcriptionally active DNA.

Authors:  J Venema; L H Mullenders; A T Natarajan; A A van Zeeland; L V Mayne
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

10.  Hereditary overexpression of adenosine deaminase in erythrocytes: evidence for a cis-acting mutation.

Authors:  E H Chen; A P Tartaglia; B S Mitchell
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.